With the annual reporting season upon us, it's time for public companies to reassess their risk factor disclosures, particularly in light of the new administration in the White House.  Health care companies and pharmaceutical companies in particular should be assessing whether proposed changes in the current state of health care laws could have a material impact on their businesses.  Another factor to consider is whether increased corporate tax rates might also require enhanced risk factor disclosure.